Approaches and problems in the development of x-ray diagnostic equipment

ékran Scientific-Production Association. Spektr Scientific-Production Association. Moscow Scientific Radiological Research Institute, Ministry of Health of the RSFSR. Translated from Meditsinskaya Tekhnika, No. 5, pp. 7–11, September–October, 1991.     

激光治疗设备的发展现状与应用前景

简要回顾了激光治疗技术的发展历史;介绍了在临床应用上具有代表性的激光治疗设备的现状和最新研究进展;给出了笔者对激光医疗设备发展趋势和应用前景的看法. Abstract： The principal and technique of laser therapy are discoursed upon in chief, current development and application of laser therapy equipment are described by introducing some lasers applied in surgery and medicine such as ophthalmology and photodynamic therapy. Finally, individual view to evolution trend of laser therapy equipment is presented.     

质子治疗设备的现状和发展

为了实现质子治疗,必须有一套比常规电子直线加速器更复杂,规模更大的质子治疗设备与系统。本文首先简要地介绍质子治疗装置的系统原理,基本结构和当前国际上的质子治疗装备的商品供应概况。在此基础上进一步论述国际质子治疗装置的现状和当前的质子治疗装置研制发展。在文的最后再简要地介绍当前国际上的已有的专用质子治疗中心近况。     

An experimental high energy therapeutic ultrasound equipment: Design and characterisation

High energy ultrasound equipment for well controlled experimental work on extracorporeal shockwave lithotripsy (ESWL) and hyperthermia has been built. The design of two sets of equipment with operating frequencies of 0.5 and 1.6 MHz, respectively, is described and characterised in terms of measured generated pressure fields. The treatment heads consist of six or seven focused ultrasound transducers. The transducers have a diameter of 50 mm each and are mounted in a hemispherical Plexiglass fixture with a geometrical focus 100 mm from the transducer surfaces. Measurements were performed in a water bath in several planes perpendicular to the central axis of the ultrasound beam, using a miniature hydrophone which was positioned with a computer controlled stepping motor system. Resulting diagram plots show well defined pressure foci, located at the geometrical foci of the transducer units.     

治疗性单克隆抗体技术

近20年来,治疗性单克隆抗体已经成为重要的生物技术药物,具有极大的开发应用价值.目前治疗性单克隆抗体的研发技术主要有转基因小鼠、鼠源抗体改造、抗体库、杂交瘤、B细胞永生化,以及B细胞移植等平台.这些技术平台发展迅速、各具特色,为治疗性单克隆抗体的开发提供了丰富多样的研究策略.     

治疗性单克隆抗体技术

近20年来,治疗性单克隆抗体已经成为重要的生物技术药物,具有极大的开发应用价值.目前治疗性单克隆抗体的研发技术主要有转基因小鼠、鼠源抗体改造、抗体库、杂交瘤、B细胞永生化,以及B细胞移植等平台.这些技术平台发展迅速、各具特色,为治疗性单克隆抗体的开发提供了丰富多样的研究策略.     

治疗性单克隆抗体技术

近20年来,治疗性单克隆抗体已经成为重要的生物技术药物,具有极大的开发应用价值.目前治疗性单克隆抗体的研发技术主要有转基因小鼠、鼠源抗体改造、抗体库、杂交瘤、B细胞永生化,以及B细胞移植等平台.这些技术平台发展迅速、各具特色,为治疗性单克隆抗体的开发提供了丰富多样的研究策略.     

治疗性单克隆抗体技术

近20年来,治疗性单克隆抗体已经成为重要的生物技术药物,具有极大的开发应用价值。目前治疗性单克隆抗体的研发技术主要有转基因小鼠、鼠源抗体改造、抗体库、杂交瘤、B细胞永生化,以及B细胞移植等平台。这些技术平台发展迅速、各具特色,为治疗性单克隆抗体的开发提供了丰富多样的研究策略。     

Clinical development of MVA-based therapeutic cancer vaccines

Tumor-associated antigens (TAAs) have been formulated into vaccines that, combined with adjuvants, cytokines or other strategies to boost the immune response, are now in clinical development. Both humoral and cellular immune responses to TAAs have been generated using these vaccines. This approach relies on the patient's own immune system generating an effective anti-tumor immune response. The advantage of this over therapy with monoclonal antibodies for the treatment of cancer is that multiple antigenic epitopes can be involved and the immune system is able to adapt to the most effective antigenic specificity for tumor growth control and rejection. In this article, we describe the clinical use of vaccinia virus, in particular modified vaccinia virus Ankara (MVA), to express TAAs in vivo and to stimulate an effective immune response to the cancer antigens.     

治疗性单克隆抗体技术

近20年来,治疗性单克隆抗体已经成为重要的生物技术药物,具有极大的开发应用价值.目前治疗性单克隆抗体的研发技术主要有转基因小鼠、鼠源抗体改造、抗体库、杂交瘤、B细胞永生化,以及B细胞移植等平台.这些技术平台发展迅速、各具特色,为治疗性单克隆抗体的开发提供了丰富多样的研究策略.